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By the standard p24 assay there was a 25 to 27% decrease in free p24 antigen in serum after storage at 4°C
over 14 days but no loss at 270°C. There was no loss at either temperature by the immune complex dissociation
(ICD) procedure. Furthermore, there was no significant loss of detectable p24 in serum by either the ICD or
the standard p24 assay after 700 days of storage at 270°C.
The human immunodeficiency virus (HIV) p24 antigen as-
say has been a useful laboratory tool for diagnosis (7, 8, 10,
13–16), prognosis (1), monitoring antiretroviral activity (2, 4, 5,
9, 12), and screening the volunteer donor blood supply (3). The
measurement of p24 antigen in patient blood as an indicator of
drug activity has been utilized over the past several years in
nearly all AIDS Clinical Trials Group (ACTG) antiretroviral
trials. In some of these trials specimens for batch p24 analysis
were stored for up to several years prior to testing. Variables
that could have affected p24 values in these studies included
storage conditions prior to freezing and the freeze-thaw pro-
cess itself. We have addressed the validity of these batched
measurements in a prospective study to experimentally deter-
mine the stabilities of both free and antibody-complexed p24
antigens under various conditions of freeze-thaw, short-term
storage, and long-term storage.
Serum specimens used in these studies were preselected for
p24 antigen positivity. Four sites participated in the short-term
storage study, during which serum (n 5 35) was separated
within 6 h of blood draw, aliquoted, and stored at 4 or at
270°C. Specimens were tested in triplicate on the day after
blood draw (i.e., day 0), and on days 7 and 14, by using stan-
dard and immune complex dissociation (ICD) procedures for a
polyclonal p24 antigen kit (Abbott Laboratories, North Chi-
cago, Ill.). Log10 p24 antigen values after 7 and 14 days at
270°C were compared with values on day 0. No detectable loss
of p24 antigen over 14 days was seen. Therefore, the values of
p24 antigen after 7 or 14 days of storage at 4°C were compared
(by the elementary t test) with the values at the same time
points for storage at 270°C both within each lab and in the
aggregate. Median standard p24 antigen values (baseline me-
dian, 307 pg/ml; range 12 to 1,725 pg/ml) at 4°C were lower
than the corresponding values at 270°C by 0.13 log10 (25%)
after 7 days and by 0.14 log10 (27%) after 14 days (Table 1). In
contrast, median ICD p24 antigen values (baseline median,
458 pg/ml; range 32 to 1,964 pg/ml) were not significantly
different through 14 days of storage for either temperature.
Aliquots for the freeze-thaw study were stored at 270°C.
Aliquots were thawed on day 0, and some were assayed and
some were refrozen. The refrozen aliquots were thawed and
either assayed or refrozen on day 7. The 7-day refrozen sam-
ples were assayed on day 14. Antigen values from either the
standard or the ICD assay were not changed over these one,
two, or three freeze-thaw events.
Serum (n 5 62, standard; n 5 69, ICD) for the long-term
study was separated within 6 h of the blood draw, aliquoted,
and frozen at 270°C at eight participating ACTG virology lab
sites. At day 0, aliquots were thawed and tested in triplicate by
both the standard and ICD procedures by using kits from
Abbott (monoclonal, n 5 3 sites; part polyclonal and mono-
clonal, n 5 2 sites), Coulter Immunology (Hialeah, Fla.) (n 5
2 sites), or E. I. DuPont de Nemours (Wilmington, Del.) (n 5
1 site). At approximately 100-day intervals, aliquots were
thawed and assayed in triplicate. If there was insufficient spec-
imen for assay at each interval, the final aliquot was saved for
a 700-day assay.
Standard curves were generated by a single assay of a com-
mon 400-pg/ml antigen standard provided by the Virology
Quality Assurance Laboratory and diluted on site. Antigen
values were calculated from the standard curves by using a
software program (Retrovirus Lab Management Program;
Dataworks Development, Inc., Seattle, Wash.). Standards and
calculations were the same for ICD assays performed in accor-
dance with the manufacturer’s instructions. However, some
samples were diluted prior to assay to bring them into the
linear range. A new batch of standards was provided between
400 and 500 days of storage.
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Some of the 442 observations for the standard assay were
eliminated due to standard curves which were problematic
(n 5 42), optical densities which fell outside the linear range of
the Abbott assay (n 5 49), and a change in DuPont kits which
resulted in an apparent antigen increase (n 5 17). For the ICD
observations (n 5 503), data which were outside the Abbott
linear range (n 5 49) or due to the change in DuPont kits (n 5
20) were eliminated. Linear models of log10 p24 concentration
as a function of storage time were used to analyze the 383
standard and 434 ICD antigen observations. The approach was
based on the assumption that the rate of change in concentra-
tion was the same for all specimens and proportional to p24
concentration; however, there was a separate intercept for
each specimen (i.e., a separate log10 p24 concentration at base-
line). Under this model, it was assumed that the change in
standards altered the estimates of p24 concentration by a con-
stant amount but did not affect the estimated rate of change in
concentration.
The ratio of p24 antigen concentration at each time point to
mean p24 concentration over time for that specimen is plotted
against days in storage in Fig. 1 (standard assay) and Fig. 2
(ICD). The reference line at 0.0 shows where an observation
would fall if the p24 antigen concentration for a specimen did
not change. Baseline values ranged from 11.6 to 1,351 pg/ml
(median, 89 pg/ml) for the standard assay and from 15.5 to
2,371 pg/ml (median, 226 pg/ml) for the ICD assay. Values
after day 500 tended to be positive, which reflected the change
of standards at that time. The vertical scatter in the ICD p24
assay results was greater than in the standard (direct) p24 assay
results.
The slight increase in p24 concentrations after day 400,
which resulted from the change in standards, complicated the
analysis. Parameter estimates from regressions for the data
from days 0 to 400 were compared with those for the data from
days 500 to 700 to determine if the change in standards affected
the relationship of p24 values with length of storage. Regres-
sion slopes for the two time periods did not differ significantly
(standard assay, P 5 0.0692; ICD assay, P 5 0.87). For the ICD
assay, the intercept for days 500 to 700 was significantly greater
than the intercept for days 0 to 400 (P 5 0.0007). No difference
in intercepts was detected for the standard assay (P 5 0.1019).
After adjusting for the change in standards, there was no
statistically significant change in p24 antigen concentration
over 700 days by either the standard assay (P 5 0.74) or the
ICD assay (P 5 0.22). The absence of a downward trend which
would reflect a loss of antigen is apparent in the graphs.
In summary, the results of the short-term study revealed a
significant loss of p24 antigen within 7 days if antigen-positive
serum was stored at 4°C and then assayed by the standard
antigen assay. However, assays of the same sera by the ICD
method showed no antigen loss over the same time period and
under the same storage conditions. We interpret the loss of
p24 antigen by the standard assay at 4°C to be due to the
formation of antigen-antibody immune complexes in the serum
within 7 days and not as an actual loss by degradation of the
antigen. Others (6) have concluded that there was no loss of
TABLE 1. Median values of HIV type 1 standard and ICD p24
antigen recovery from the phase 1 short-term stability study
Assay type
Difference between the refrigerator and freezer p24
antigen value (log10) at day
0 7 14
Standard 20.017 20.13 20.14
ICD 0.002 20.009 0.00
FIG. 1. Plot of log10 p24 concentration at each determination minus the mean of log10 p24 concentration over all determinations for that sample against days in
storage by the standard assay.
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antigen for up to 35 days of storage at either room temperature
or 4°C as determined by the ICD procedure. However, signif-
icant amounts of detectable antigen were lost after 2 days at
room temperature and after 4 days at 4°C as assayed with the
standard procedure (6).
Circumstances may arise during clinical testing which neces-
sitate assaying material that has undergone multiple freeze-
thaw cycles. The data from this study showed that multiple
freeze-thaw events did not have a significant effect on the
ability to detect p24 antigen in serum.
The aggregate data for the 2-year storage study showed that
storage of serum at 270°C allowed for full recovery of a wide
range of p24 levels by either the standard or the ICD proce-
dures. These results are reassuring with regard to the interpre-
tation of previous ACTG clinical trials carried out over a
period of years in which p24 levels were measured in batch
assays after several hundred days of storage. Had antigen de-
graded significantly during storage of the baseline samples, a
drug treatment effect might not have been observed in cases
where it did in fact exist. However, in a retrospective compar-
ison of values from real time assays with values from batch
assays of stored aliquots of the same samples, the differences
between the results from the batch and real time assays were
negatively correlated with storage time (11). The conditions for
short-term storage, prior to long-term storage at 270°C, in the
retrospective analysis were less rigidly controlled than they
were in our study. This could account for the different out-
comes. Finally, the conclusions obtained in our study are lim-
ited to serum samples and storage at 270°C. They may not
apply to plasma samples or storage at 220°C.
The results presented here are important for ongoing and
future studies that depend on the measurement of p24 antigen
including clinical trials, blood bank testing, and diagnosis of
pediatric HIV infection. Optimal conditions for processing of
serum for p24 antigen testing should include storage at 4°C
prior to freezing within 1 day of the blood draw and long-term
storage at 270°C.
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